Free Trial

AstraZeneca (AZN) Stock Price, News & Analysis

AstraZeneca logo
$71.42
+0.27 (+0.38%)
(As of 11/1/2024 ET)

About AstraZeneca Stock (NASDAQ:AZN)

Key Stats

Today's Range
$71.30
$71.86
50-Day Range
$71.15
$87.62
52-Week Range
$60.47
$87.68
Volume
3.47 million shs
Average Volume
3.43 million shs
Market Capitalization
$221.44 billion
P/E Ratio
34.50
Dividend Yield
1.37%
Price Target
$89.75
Consensus Rating
Moderate Buy

Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
88th Percentile Overall Score

AZN MarketRank™: 

AstraZeneca scored higher than 88% of companies evaluated by MarketBeat, and ranked 116th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 7 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    AstraZeneca has only been the subject of 3 research reports in the past 90 days.

  • Read more about AstraZeneca's stock forecast and price target.
  • Earnings Growth

    Earnings for AstraZeneca are expected to grow by 16.54% in the coming year, from $4.05 to $4.72 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AstraZeneca is 34.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.25.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AstraZeneca is 34.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.56.

  • Price to Earnings Growth Ratio

    AstraZeneca has a PEG Ratio of 1.32. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    AstraZeneca has a P/B Ratio of 5.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AstraZeneca's valuation and earnings.
  • Percentage of Shares Shorted

    0.13% of the outstanding shares of AstraZeneca have been sold short.
  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AstraZeneca has recently decreased by 25.23%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    AstraZeneca pays a meaningful dividend of 1.38%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    AstraZeneca does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of AstraZeneca is 47.34%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 20.76% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.

  • Read more about AstraZeneca's dividend.
  • Percentage of Shares Shorted

    0.13% of the outstanding shares of AstraZeneca have been sold short.
  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AstraZeneca has recently decreased by 25.23%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    AstraZeneca has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 26 news articles for AstraZeneca this week, compared to 18 articles on an average week.
  • Search Interest

    15 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 17 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AstraZeneca insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 20.35% of the stock of AstraZeneca is held by institutions.

  • Read more about AstraZeneca's insider trading history.
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZN Stock News Headlines

Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
AstraZeneca’s China Operations Amid Leadership Investigation
AstraZeneca reports China President currently under investigation
See More Headlines

AZN Stock Analysis - Frequently Asked Questions

AstraZeneca's stock was trading at $67.35 at the beginning of 2024. Since then, AZN stock has increased by 6.0% and is now trading at $71.42.
View the best growth stocks for 2024 here
.

AstraZeneca PLC (NASDAQ:AZN) issued its quarterly earnings results on Thursday, July, 25th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.01. AstraZeneca's quarterly revenue was up 9.1% compared to the same quarter last year.

Shares of AstraZeneca split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were payable to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

AstraZeneca subsidiaries include these companies: Alexion Pharmaceuticals, Takeda Respiratory Business, AcertaPharma, ZS Pharma, Almirall, Pearl Therapeutics, Omthera Pharmaceuticals, and more.

Top institutional shareholders of AstraZeneca include Swedbank AB (0.09%), Raymond James & Associates (0.08%), abrdn plc (0.04%) and Assenagon Asset Management S.A. (0.03%).
View institutional ownership trends
.

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Chevron (CVX), BlackRock (BLK), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Bristol-Myers Squibb (BMY) and Tesla (TSLA).

Company Calendar

Last Earnings
7/25/2024
Ex-Dividend for 9/9 Dividend
8/09/2024
Dividend Payable
9/09/2024
Today
11/02/2024
Next Earnings (Confirmed)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AZN
Employees
89,900
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$89.75
High Stock Price Target
$97.00
Low Stock Price Target
$82.00
Potential Upside/Downside
+25.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$5.96 billion
Pretax Margin
15.77%

Debt

Sales & Book Value

Annual Sales
$45.81 billion
Cash Flow
$5.29 per share
Book Value
$12.63 per share

Miscellaneous

Outstanding Shares
3,100,590,000
Free Float
N/A
Market Cap
$221.44 billion
Optionable
Optionable
Beta
0.46

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:AZN) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners